Rutinib

Ruxolitinib(鲁索利替尼)

Composition: Ruxolitinib Phosphate INN 1.5% cream.

Indication: Ruxolitinib is a Janus kinase (JAK) inhibitor indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Dosage and administration: A thin layer of cream should be applied to the affected areas BID of up to 20% body surface area; not to exceed >60 g/week. It should stop using when signs and symptoms (eg, itch, rash, redness) of atopic dermatitis resolve. If signs and symptoms do not improve within 8 weeks, re-examine patient. Or, as directed by the registered physician.

Use in pregnancy and lactation: There is no data available.

Packing: Each tube contains 30 gm cream.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.